PreClinOmics provides discovery, analytical, and ADME/PK services, safety/non-GLP toxicology services, and genetic models. The acquisition adds highly translational models to effectively screen compounds for efficacy and reduce the complications of these diseases. The models in the PreClinOmics product line develop adult onset type 2 diabetes and all the diabetic complications without relying on mutations in the leptin signaling. Mutations in the leptin gene/receptor have never been identified as relevant to the onset of the human disease.
“The acquisition of PreClinOmics will allow CrownBio to create a center of excellence in global translational drug development specifically for cardiovascular and metabolic disease,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “We are confident that the acquisition will ultimately result in greater success in clinical trials and lower the cost of drug development for diseases that produce some of the highest economic costs in the world.”
“We are thrilled to join Crown Bioscience. The drug development industry will now have a single source that offers the best models available in both cardiovascular and metabolic diseases,” said Joseph Pesek, chief executive officer and co-founder of PreClinOmics, Inc. “We are excited for the opportunities the acquisition has given us, especially with the reputation that CrownBio has earned with the experience and global resources it offers the market.”